Introduction {#S0001}
============

Atopic dermatitis (AD) is a chronic, relapsing and pruritic inflammatory skin disease, characterized by typical localization and a specific image of skin lesions, with coexistence of other atopic diseases. Diagnostic criteria for AD elaborated by Hanifin and Rajka have been universally accepted, due to a large variety of the clinical picture \[[@CIT0001]\].

Pruritus is one of the most common symptoms in AD, practically occurring in each patient. Therefore, it has been included as one of the four major diagnostic criteria \[[@CIT0001], [@CIT0002]\]. Scoring the intensity of pruritus is an integral part of the SCORAD (Severity SCORing of Atopic Dermatitis) index, which is commonly used to determine the severity of the disease \[[@CIT0003]\]. The etiology of pruritus in AD is not fully explained, however the participation of some endogenous mediators, neurotransmitters, arachidonic derivatives and cytokines has been taken into consideration in itch pathophysiology \[[@CIT0004]\]. Recently, in numerous studies, interleukin-31 (IL-31) has been associated with the pathogenesis of pruritus in chronic inflammatory skin diseases \[[@CIT0005]\]. This relatively newly described cytokine is preferentially produced by activated T cells skewed towards Th2 \[[@CIT0006]\]. Interleukin-31 is related to the IL-6 cytokine family \[[@CIT0007]\]. It signals through a heterodimeric receptor composed of IL-31 receptor α (IL-31RA) also known as gp130-like receptor (GPL) and oncostatin M receptor (OSMR) \[[@CIT0006], [@CIT0008], [@CIT0009]\]. Dillon *et al*. demonstrated the development of severe pruritus and skin lesions similar to AD in transgenic mice with overexpression of IL-31 \[[@CIT0007]\]. Other studies revealed that IL-31 serum levels are higher in patients with AD comparing to healthy controls \[[@CIT0010]\]. Moreover, serum IL-31 levels correlate with the disease activity in atopic patients \[[@CIT0011]\]. Evidence of the importance of IL-31 in the pathogenesis of pruritus is also present in studies on IL-31 inhibitors relevant to the treatment of AD \[[@CIT0012], [@CIT0013]\].

Aim {#S0002}
===

The aim of the study was to assess the correlation between serum IL-31 levels and the disease severity in patients with AD.

Material and methods {#S0003}
====================

Twenty-five children (16 girls and 9 boys) with AD aged from 4 months to 17 years (mean age: 4.2 years) were enrolled in the study. The control group (CG) consisted of 20 healthy children diagnosed due to recurrent diseases of the respiratory tract with no immunodeficiencies, atopic and dermatological diseases with accompanying pruritus. Atopic dermatitis was diagnosed according to criteria proposed by Hanifin and Rajka \[[@CIT0001]\]. Disease severity was determined using the SCORAD (Severity SCORing of Atopic Dermatitis) index including subjective symptoms, extent and intensity of the lesions. Subjective itch intensity was measured using a patient/parent-reported 0-10 scale (0: no pruritus, 10: extremely severe pruritus). Sixteen children had moderate AD (SCORAD index 25-50) and 9 children had severe AD (SCORAD index over 50). Children included in the study were hospitalized in the Department of Pediatrics, Immunology and Nephrology of the Polish Mother\'s Research Memorial Institute in Lodz in 2011-2012.

Serum IL-31 levels were measured using ELISA with standard kits from EIAab R&D Systems. Serum was stored at --30°C until assayed. All analyses were performed according to the manufacturer\'s protocol. The tests were performed in the immunological laboratory -- APC Medical Analysis in Lodz.

Statistical analysis {#S20004}
--------------------

The statistical analysis was performed with the use of Statistica programme 10.0PL (StatSoft, Poland). The data were presented as a median value and interquartile range (IQR) or as a mean value and standard error (SE) according to the normal distribution and the number of patients in the group. Normal distribution was tested with Shapiro-Wilk test, accepting *p* \< 0.05 as the value different from normal distribution. In all cases, statistically significant probability of α error (*p*) was considered as less than 0.05. Correlations between serum IL-31 level in the study and control groups and the disease severity in AD patients were assessed using *U* Mann-Whitney test. The Spearman rank test was used to evaluate the relationship between serum levels of IL-31 and itch intensity.

Results {#S0005}
=======

Serum IL-31 levels in both groups {#S20006}
---------------------------------

[Table 1](#T0001){ref-type="table"} shows the median and quartile values of serum IL-31 level in both groups. We found significant differences between the group of patients with AD and CG ([Figure 1](#F0001){ref-type="fig"}).

![Comparison of the median and quartil values of serum IL-31 levels between the group of patients with AD and the control group](PDIA-30-21576-g001){#F0001}

###### 

The median and quartile values of serum IL-31 level in AD and healthy children (CG). Significant differences be-tween research groups were found

  Group               Concentration of IL-31              
  ------------------- ------------------------ ---------- ----------
  Control             8.1300                   17.3200    35.9100
  Atopic dermatitis   309.0000                 350.6000   412.5000
  All                 19.8800                  252.2000   350.9000

The statistical analysis showed that serum IL-31 level was significantly higher in AD than in the control group (AD vs. CG, *p* \< 0.000001).

Correlation between serum IL-31 level and the disease severity {#S20007}
--------------------------------------------------------------

Serum IL-31 level was inversely correlated with the disease severity by SCORAD index (*p* = 0.1). The test result close to 0.1, and [Figure 2](#F0002){ref-type="fig"} showing the median and quartile values in the group of patients with severe AD (SCORAD \> 50 points) and moderate AD (SCORAD 25--50 points) are suggestive of a small number of patients in groups.

![Comparison of IL-31 level in patients with severe AD (SCORAD \> 50) and moderate AD (SCORAD 25--50)](PDIA-30-21576-g002){#F0002}

Correlation between serum IL-31 level and itch intensity {#S20008}
--------------------------------------------------------

Serum cytokine level was not significantly correlated with itch intensity in patients with AD (*p* = 0.372), as shown in [Table 2](#T0002){ref-type="table"}.

###### 

Correlation of itch intensity with serum IL-31 level

  Pair of variables   *N*   Spearman R   *t* (*N* -- 2)   Value of *p*
  ------------------- ----- ------------ ---------------- --------------
  Itch and IL-31      25    0.186388     0.909828         0.372349

Discussion {#S0009}
==========

In the present study, we have shown that serum IL-31 level was higher in children with AD than in healthy patients, which is consistent with the results given by other authors. There are numerous reports in the literature indicating the involvement of IL-31 in the pathogenesis of AD.

Sonokoly *et al*. and Raap *et al*., as one of the first, achieved significantly higher serum IL-31 levels in the group of patients with AD \[[@CIT0011]\]. Similar results were obtained by Ezzat *et al*. and Kim *et al*., comparing serum IL-31 levels in AD patients with healthy ones. Analysis of serum IL-31 levels were performed in both cases using ELISA method, obtaining significantly higher results in AD patients \[[@CIT0014], [@CIT0015]\]. Nobbe *et al*. demonstrated increased immunoreactivity of IL-31 in infiltrating inflammatory cells in AD compared with pruritic or Th2-mediated diseases \[[@CIT0016]\]. Szegedi *et al*. proved that T cells in chronic AD skin produce IL-31 and that AD lesions contain increased levels of these IL-31-producing T cells \[[@CIT0017]\].

In this study there was no correlation between the severity of the disease and serum IL-31 levels, which may be partly consistent with Neiss *et al*.\'s study, who found statistically increased mRNA levels of IL-31 in biopsy specimens of patients with AD, irrespective of the disease severity \[[@CIT0018]\]. Similar reports with presented results can also be found in the literature.

Ezzat *et al*. show a positive correlation by classifying patients into three groups: severe, moderate and mild AD \[[@CIT0014]\]. Kim *et al*. point out to a positive correlation and a strong interrelation between serum levels of IL-31, the degree of the disease severity and mRNA level for this cytokine in skin biopsies of patients with AD \[[@CIT0015]\].

In the present study we have also shown no correlation between itch intensity and serum level of tested cytokine in AD patients. Kim *et al*. obtained different results and demonstrated a correlation between subjective itch intensity and serum IL-31 levels, what was suggestive of a possible involvement of IL-31 as a mediator inducing not only inflammation, but also pruritus in AD.

Important factors in the analysis of the presented results are subjectivity of pruritus severity assessment and the number of the research groups. Studies performed on a mouse model of dermatitis using a monoclonal antibody neutralizing the effects of IL-31 are promising, due to no conclusive results that indicate a role of IL-31 not only in the process of itching, but also its intensity. Studies show a significant reduction in itching and inflammatory symptoms \[[@CIT0019]\]. Venereau *et al*. generated in experimental studies and gave a description of the potential antagonist for IL-31 formed by external portions of oncostatin M receptor (OSMR) and gp130-like receptor (GPL) fused with a linker, which neutralized activity of IL-31 in different bioassays \[[@CIT0013]\].

Certainly, further research on the pathomechanism of pruritus in atopic dermatitis is warranted for the complete understanding of the relations described in the literature.

Conclusions {#S0010}
===========

Serum IL-31 level was significantly higher in AD than in healthy children. There was no correlation between the disease severity, itch intensity and serum level of the tested cytokine.
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